Ameno

About Gameto

Gameto is a private, clinical-stage biotech founded in 2020, leveraging a proprietary induced pluripotent stem cell (iPSC) platform to engineer ovarian support cells. Its lead asset, Fertilo, is in Phase 3 trials for improving IVF outcomes, while earlier-stage programs target ovarian disease (Deovo) and menopause (Ameno). The company is backed by venture capital and a recent award from ARPA-H, positioning it at the forefront of innovation in the underserved women's health market.

Therapeutic Areas